NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022

Caudell, Jimmy J.; Gillison, Maura L.; Maghami, Ellie; Spencer, Sharon; Pfister, David G.; Adkins, Douglas R.; Birkeland, Andrew C.; Brizel, D.M.; Busse, Paul M.; Cmelak, Anthony J.; Colevas, A. Dimitrios; Eisele, David W.; Galloway, Thomas J.; Geiger, J.L.; Haddad, Robert I.; Hicks, Wesley L.; Hitchcock, Ying J.; Jimeno, Antonio; Leizman, Debra S.; Mell, Loren K.; Mittal, Bharat B.; Pinto, Harlan A.; Rocco, James W.; Rodriguez, Cristina P.; Savvides, P.; Schwartz, David L.; Shah, Jatin P.; Sher, David J.; John, Maie St.; Weber, Randal S.; Weinstein, Gregory S.; Worden, Frank; Bruce, Justine Y.; Yom, Sue S.; Zhen, Weining; Burns, Jennifer L.; Darlow, Susan

doi:10.6004/jnccn.2022.0016

Cited by 288 publications

(222 citation statements)

References 93 publications

(141 reference statements)

Supporting

Mentioning

215

Contrasting

Unclassified

Order By: Relevance

“…(1) Psychological Distress Management Screening Tool . The distress management screening measure (DMSM) is recommended by the National Comprehensive Cancer Network (NCCN) [ 13 ] and consists of two parts: (1) distress thermometer (DT), using 0–10 to indicate the degree of psychological distress, which is marked by the patient according to the average distress level experienced in the past 1 week. 0–3 is mild psychological distress; 4–6 is moderate psychological distress; 7–10 is severe psychological distress; (2) problem list (PL), including various problems encountered by cancer patients after illness, a total of 5 dimensions and 53 questions: physical problems (3) family practical problems (4) emotions questions (5) family questions (6) spiritual/religious questions.…”

Section: Methodsmentioning

confidence: 99%

“…(1) Psychological Distress Management Screening Tool. e distress management screening measure (DMSM) is recommended by the National Comprehensive Cancer Network (NCCN) [13] and consists of two parts: (1) distress thermometer (DT), using 0-10 to indicate the degree of psychological distress, which is marked by the patient according to the average distress level experienced in the past 1 week. 0-3 is mild psychological distress; 4-6 is moderate psychological distress; 7-10 is severe psychological distress;…”

Section: Survey Toolsmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of Current Situation and Influencing Factors of Psychological Distress in Patients with Lung Cancer during Perioperative Period

Zhang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To explore the degree of psychological distress in patients with lung cancer during the perioperative period and analyze its influencing factors. Method. A cross-sectional survey was conducted on 372 perioperative patients with lung cancer admitted to our hospital by a convenience sampling method using general data collection and psychological pain thermometer scores. Results. The psychological distress score of 372 patients with lung cancer in the perioperative period was 4.10 ± 2.88. The psychological distress of patients was related to physical problems, practical problems, medical expenses, and family communication problems. Logistic regression analysis showed that gender, economic burden caused by disease, child care, lack of interest in daily activities, and anxiety were the main factors affecting the degree of suffering of lung cancer patients. Conclusion. The proportion of perioperative lung cancer patients with a psychological distress score ≥4 points was 55.6%, and more than half of the perioperative patients with lung cancer had a moderate level of psychological distress. Medical staff should pay attention to the management of the psychological distress of patients with lung cancer during the perioperative period, help patients solve practical problems in the process of cancer treatment, strengthen society’s attention to female lung cancer patients, and establish a comprehensive cancer public welfare organization group.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Survey Toolsmentioning

confidence: 99%

Analysis of Current Situation and Influencing Factors of Psychological Distress in Patients with Lung Cancer during Perioperative Period

Zhang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Radiotherapy is one of a promising treatment strategy for cancer. In HNSCC, combination of high-dose cisplatin administration with radiotherapy is recommended as a standard of care for the postoperative HNSCC patients who are at intermediate/high risk of recurrence [ 129 ]. In various cancer, the development of effective radiosensitizers can improve the survival rates.…”

Section: Introductionmentioning

confidence: 99%

TMEM16A as a potential treatment target for head and neck cancer

Okuyama

Yanamoto

2022

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Transmembrane protein 16A (TMEM16A) forms a plasma membrane-localized Ca2+-activated Cl- channel. Its gene has been mapped to an area on chromosome 11q13, which is amplified in head and neck squamous cell carcinoma (HNSCC). In HNSCC, TMEM16A overexpression is associated with not only high tumor grade, metastasis, low survival, and poor prognosis, but also deterioration of clinical outcomes following platinum-based chemotherapy. Recent study revealed the interaction between TMEM16A and transforming growth factor-β (TGF-β) has an indirect crosstalk in clarifying the mechanism of TMEM16A-induced epithelial-mesenchymal transition. Moreover, human papillomavirus (HPV) infection can modulate TMEM16A expression along with epidermal growth factor receptor (EGFR), whose phosphorylation has been reported as a potential co-biomarker of HPV-positive cancers. Considering that EGFR forms a functional complex with TMEM16A and is a co-biomarker of HPV, there may be crosstalk between TMEM16A expression and HPV-induced HNSCC. EGFR activation can induce programmed death ligand 1 (PD-L1) synthesis via activation of the nuclear factor kappa B pathway and JAK/STAT3 pathway. Here, we describe an interplay among EGFR, PD-L1, and TMEM16A. Combination therapy using TMEM16A and PD-L1 inhibitors may improve the survival rate of HNSCC patients, especially those resistant to anti-EGFR inhibitor treatment. To the best of our knowledge, this is the first review to propose a biological validation that combines immune checkpoint inhibition with TMEM16A inhibition.

show abstract

Section: Introductionmentioning

confidence: 99%

“…The recommended regimen for primary definitive treatment is concurrent chemoradiotherapy plus (neo)adjuvant cisplatin-based chemotherapy [ 6 ]. Cisplatin/gemcitabine is the first-line therapy for recurrent or metastatic disease (R/M) [ 6 – 8 ]. Most patients with R/M NPC have already exhausted platinum-based therapy, and there is no substantial evidence to support the choice of treatment in subsequent lines [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Alshamsan

Gad

Alata

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. Numerous chemotherapeutic agents have antitumor activity in recurrent/metastatic (R/M) nasopharyngeal cancer (NPC). Evidence of capecitabine’s effectiveness as monotherapy is limited. Capecitabine tolerability in solid malignancies has ethnic and geographical variability. We investigated capecitabine’s tolerability and identified potential prognostic factors for clinical outcomes in R/M NPC. Methods. A consecutive retrospective cohort of patients who received capecitabine as the first recurrence, second- or third-line monotherapy for metastatic NPC (2011–2019) was reviewed concerning patient characteristics, pathological features, treatment outcomes, and toxicity. Results. Fifty-one patients were eligible (median age at diagnosis: 42 [35.5–52.5] years). Most patients (78.4%) tolerated a standard oral dose of 1,250 mg/m2 capecitabine (2 weeks on/1 week off) in a 3-week cycle. The objective response rate was 49%, and the disease control rate was 66.7%, with a median response duration of 6.2 months. Hand-foot syndrome (HFS) was associated with a higher objective response rate (odds ratio, 5.1 [95% confidence interval: 1.18–21.98]; P = 0.02 ). The median follow-up duration was 17.8 (interquartile range: 7.8–30.4) months. The median (95% confidence interval) progression-free survival and overall survival were 6.6 (4.3–8.8) and 32.7 (25.9–39.5) months, respectively. HFS ( P = 0.02 ), better performance status ( P = 0.02 ), and absence of brain metastasis ( P = 0.04 ) were associated with prolonged progression-free survival. Conclusion. Capecitabine monotherapy is effective and well-tolerated as a palliative treatment for R/M NPC. Despite the lower incidence of HFS in our patients, it remained a favorable prognostic factor for objective response and progression-free survival.

show abstract

NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022

Cited by 288 publications

References 93 publications

Analysis of Current Situation and Influencing Factors of Psychological Distress in Patients with Lung Cancer during Perioperative Period

Analysis of Current Situation and Influencing Factors of Psychological Distress in Patients with Lung Cancer during Perioperative Period

TMEM16A as a potential treatment target for head and neck cancer

Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Contact Info

Product

Resources

About